[{"_id":"551f89c131cae9239deb20d9","会社名":"小林製薬(株)【4967】","証券コード":"4967","決算期":"2014年3月期","会計方式":"日本方式","決算発表日":"2014年4月30日","決算月数":"12か月","売上高":"127,293百万円","営業利益":"18,122百万円","経常利益":"18,769百万円","当期利益":"12,307百万円","EPS（一株当たり利益）":"300.55円","調整一株当たり利益":"---","BPS（一株当たり純資産）":"3,098.32円","総資産":"170,919百万円","自己資本":"126,870百万円","資本金":"3,450百万円","有利子負債":"6百万円","自己資本比率":"74.2%","ROA（総資産利益率）":"7.50%","ROE（自己資本利益率）":"10.18%","総資産経常利益率":"11.44%","__v":0,"日付":"2015-04-04T06:50:41.744Z"},{"_id":"551f89c131cae9239deb20da","会社名":"小林製薬(株)【4967】","証券コード":"4967","決算期":"2013年3月期","会計方式":"日本方式","決算発表日":"2013年5月1日","決算月数":"12か月","売上高":"121,532百万円","営業利益":"16,903百万円","経常利益":"18,677百万円","当期利益":"12,176百万円","EPS（一株当たり利益）":"297.37円","調整一株当たり利益":"---","BPS（一株当たり純資産）":"2,805.27円","総資産":"157,106百万円","自己資本":"114,872百万円","資本金":"3,450百万円","有利子負債":"4百万円","自己資本比率":"73.1%","ROA（総資産利益率）":"7.98%","ROE（自己資本利益率）":"11.24%","総資産経常利益率":"12.25%","__v":0,"日付":"2015-04-04T06:50:41.744Z"},{"_id":"551f89c131cae9239deb20db","会社名":"小林製薬(株)【4967】","証券コード":"4967","決算期":"2012年3月期","会計方式":"日本方式","決算発表日":"2012年5月1日","決算月数":"12か月","売上高":"131,166百万円","営業利益":"19,298百万円","経常利益":"20,092百万円","当期利益":"11,726百万円","EPS（一株当たり利益）":"286.36円","調整一株当たり利益":"---","BPS（一株当たり純資産）":"2,484.08円","総資産":"147,890百万円","自己資本":"101,720百万円","資本金":"3,450百万円","有利子負債":"5百万円","自己資本比率":"68.8%","ROA（総資産利益率）":"8.31%","ROE（自己資本利益率）":"12.16%","総資産経常利益率":"14.24%","__v":0,"日付":"2015-04-04T06:50:41.745Z"},{"_id":"551f89c131cae9239deb20dc","会社名":"小林製薬(株)【4967】","証券コード":"4967","決算期":"2013年3月期","会計方式":"日本方式","決算発表日":"2013年5月1日","決算月数":"12か月","売上高":"121,532百万円","営業利益":"16,903百万円","経常利益":"18,677百万円","当期利益":"12,176百万円","EPS（一株当たり利益）":"297.37円","調整一株当たり利益":"---","BPS（一株当たり純資産）":"2,805.27円","総資産":"157,106百万円","自己資本":"114,872百万円","資本金":"3,450百万円","有利子負債":"4百万円","自己資本比率":"73.1%","ROA（総資産利益率）":"7.98%","ROE（自己資本利益率）":"11.24%","総資産経常利益率":"12.25%","__v":0,"日付":"2015-04-04T06:50:41.752Z"}]